Postrecurrence survival for pediatric extracranial malignant germ cell tumors: A report from the Malignant Germ Cell Tumors International Collaborative (MaGIC) Group.

10074 Background: Post-recurrence survival (PRS) of children and adolescents with malignant germ cell tumors (MGCTs) has not previously been described, due to the limited sample size of relapsed patients in clinical trials. Methods: Data from 7 pediatric extracranial GCT trials conducted by the Children’s Oncology Group (COG, United States) or the Children’s Cancer and Leukemia Group (CCLG, United Kingdom) between 1985-2009 were merged. The COG and CCLG trials differed mainly in the type of platinum agent used for upfront treatment (cisplatin or carboplatin, respectively), and event-free survival after either treatment were not significantly different, as previously reported. Kaplan-Meier survival curves and Cox regression were used to analyze the effects of potential predictor variables on PRS. Results: Among 1,107 children in the pooled dataset, 700 MGCT patients received treatment with platinum-based chemotherapy. 72 of these patients experienced a relapse or refractory disease. For these 72 patients, ...